Guyer Charles Greg 4

What Happened
Greg Guyer, Executive Vice President and Chief Technical Officer of BioMarin Pharmaceutical Inc. (BMRN), was granted/awarded a total of 15,222 restricted stock units (RSUs) on Feb 25, 2026. The filing reports three award components: 6,176 RSUs, 6,675 RSUs, and 2,371 RSUs, each acquired at $0.00 (i.e., no cash payment). These RSUs are convertible into common shares on a 1:1 basis when they vest.

Key Details

• Transaction date: 2026-02-25; filing date: 2026-02-26. Price reported: $0.00 per RSU (award).
• Total RSUs awarded: 15,222 (6,176 + 6,675 + 2,371).
• Vesting: RSUs are earned but vest on March 15, 2026, contingent on Guyer's continued service through that date, with potential earlier vesting upon certain events.
• How they were earned: Awards are performance-based covering 2023–2025:
  • One component tied to relative total shareholder return (TSR) (F2).
  • One component tied to the number/nature of development goals achieved (F4).
  • One component tied to core operating margin over specified periods (F5).
  • The transaction date reflects Compensation Committee certification that the RSUs were earned (F1).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: Filing appears timely (transaction 2/25/2026, Form 4 filed 2/26/2026); no late filing flag indicated.

Context
These are performance-based RSU awards (not a purchase or sale), so they do not involve cash changing hands now. RSUs indicate compensation tied to company performance and future service; they convert to common shares if and when they vest. For retail investors, awards reflect board/committee recognition of performance metrics being met but do not, by themselves, signal an insider buying or selling company stock.